Triton Agreement and Precision Study

The objectives of this study are to compare the agreement and precision between Topcon DRI OCT Triton and 3D OCT-1 Maestro with RDB by measuring the thickness layers.

Inclusion criteria

for Normal Group

• Subjects 18 years of age or older on the date of informed consent
• Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
• Subjects presenting at the site with normal eyes bilaterally (cataracts are acceptable)
• IOP ≤ 21 mmHg bilaterally
• BCVA 20/40 or better bilaterally

Exclusion criteria

for Normal Group

• Subjects unable to tolerate ophthalmic imaging
• Subjects with ocular media not sufficiently clear to obtain acceptable OCT images
• HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on manufacturer's recommendation), defined as fixation losses > 20% or false positives > 33%, or false negatives > 33%
• Visual field defects consistent with glaucomatous optic nerve damage based on at least one of the following two findings:

• On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;
• Glaucoma hemi-field test "outside normal limits."
• Narrow angle
• History of leukemia, dementia or multiple sclerosis
• Concomitant use of hydroxychloroquine and chloroquine

Inclusion criteria

for Glaucoma Group

• Subjects 18 years of age or older on the date of informed consent
• Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
• BCVA 20/40 or better in the study eye
• Visual field defects consistent with glaucomatous optic nerve damage based on at least one of the following two findings:

• On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;
• Glaucoma hemi-field test "outside normal limits."
• Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities:

• Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles with or without disc hemorrhage;
• Localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles; or
• Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue

Exclusion criteria

for Glaucoma Group

• Subjects unable to tolerate ophthalmic imaging
• Subject with ocular media not sufficiently clear to obtain acceptable OCT images
• HFA visual field (24-2 Sita Standard, white on white) result unreliable, defined as fixation losses > 20% or false positives > 33%, or false negatives > 33% in the study eye
• Presence of any ocular pathology except glaucoma in the study eye (cataracts are acceptable)
• History of leukemia, dementia or multiple sclerosis
• Concomitant use of hydroxychloroquine and chloroquine

Inclusion criteria

for Retina Disease Group

• Subjects 18 years of age or older on the date of informed consent
• Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
• Subjects presenting at the site with retinal disease
• IOP ≤ 21 mmHg in the study eye
• BCVA 20/400 or better in the study eye
• Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Cystoid Macula Edema, and others

Exclusion criteria

for Retinal Disease Group

• Subjects unable to tolerate ophthalmic imaging
• Subject with ocular media not sufficiently clear to obtain acceptable OCT images
• Presence of glaucoma or any ocular pathology other than a Retinal pathology (e.g., cornea pathology) in the study eye (cataracts are acceptable)
• Narrow angle in the study eye
• History of leukemia, dementia or multiple sclerosis
• Concomitant use of hydroxychloroquine and chloroquine